Physician profile
Antonio Rivera
NPI 1114033511
$2,524.95
in general payments reported to CMS, 2019-2025
26 companies · $395 in 2025
The $395 reported for 2025 was more than what 75% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $135 · 2021: $379 · 2022: $337 · 2023: $378 · 2024: $677 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $445.30 | 2021-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $442.09 | 2019-2024 | Ztlido |
| Pfizer INC. | $357.88 | 2024-2025 | |
| Abbvie INC. | $285.87 | 2021-2025 | Qulipta |
| Horizon Therapeutics Plc | $149.17 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $105.20 | 2019-2022 | |
| Angiodynamics, INC. | $93.77 | 2022 | |
| Lundbeck LLC | $71.02 | 2019 | |
| Antares Pharma, INC. | $62.99 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $59.15 | 2024-2025 | Horizant |
| Almatica Pharma LLC | $55.64 | 2022-2023 | Gralise |
| Idorsia Pharmaceuticals US INC | $52.45 | 2023-2024 | Quviviq |
| Biodelivery Sciences International, INC. | $50.87 | 2019-2021 | |
| Ibsa Pharma INC. | $50.17 | 2023-2024 | Tirosint, Licart, Tirosint |
| Ucb, INC. | $37.91 | 2025 | Nayzilam, Briviact |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $29.84 | 2021 | |
| West Therapeutics Development, LLC | $27.73 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.96 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $22.09 | 2019 | |
| Clarus Therapeutics INC. | $18.02 | 2021 | |
| Metacel Pharmaceuticals LLC | $16.91 | 2023 | Ozobax |
| Axsome Therapeutics, INC. | $15.69 | 2023 | Sunosi |
| Daiichi Sankyo INC. | $14.44 | 2019 | |
| Eisai INC. | $13.69 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.69 | 2022 | |
| Pernix Therapeutics Holdings, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.